Darmstadt

Lucid Welcomes Marc Winterhoff as Chief Operating Officer

Retrieved on: 
Tuesday, November 7, 2023
Lucid Motors, Lucid Air, Silicon, Darmstadt, Technischer Überwachungsverein, Engineering, Growth, Marketing, Electronics, Roland Berger (company), Lucid

Mr. Winterhoff joins Lucid from Roland Berger's automotive practice and brings a proven record of success to Lucid: operational leadership for large automotive manufacturers; managing manufacturing and cost efficiency; introduction of sales, service, and new mobility concepts; and long-term strategies for renowned automotive brands.

Key Points: 
  • Mr. Winterhoff joins Lucid from Roland Berger's automotive practice and brings a proven record of success to Lucid: operational leadership for large automotive manufacturers; managing manufacturing and cost efficiency; introduction of sales, service, and new mobility concepts; and long-term strategies for renowned automotive brands.
  • "We are delighted to welcome Marc to Lucid," said Peter Rawlinson, CEO and CTO, Lucid Group.
  • "I couldn't be more excited to join Lucid and be part of such a stellar group," said Mr. Winterhoff.
  • Mr. Winterhoff graduated with a master's degree in electrical and electronics engineering and management from the Technische Universität Darmstadt.

Universal Display Corporation Announces First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Consumer Electronics, Technology, Professional Services, Semiconductor, Research, Nanotechnology, Alternative Energy, Energy, Science, Hardware, Finance, Darmstadt, Lighting, Growth, Merck, Universal Display Corporation, Ecosystem, Merck Group, Acquisition, OLED, Pharmaceutical industry, Video game

Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today reported financial results for the first quarter ended March 31, 2023.
  • “Our first quarter results were in-line with our expectations and we are reaffirming our full year 2023 outlook,” said Brian Millard, Vice President and Chief Financial Officer of Universal Display Corporation.
  • Revenue from material sales was $70.2 million in the first quarter of 2023 as compared to $86.7 million in the first quarter of 2022.
  • Operating income was $45.4 million in the first quarter of 2023 as compared to $62.3 million in the first quarter of 2022.

EQS-News: Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres AG:

Retrieved on: 
Friday, February 3, 2023
Internet, West Coast of Vancouver Island Aquatic Management Board, Marketing, City, FY, Patient, AG, Darmstadt, Advertising, Generic drug, Pharmaceutical industry, Centaur

Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres AG:

Key Points: 
  • Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres AG:
    The issuer is solely responsible for the content of this announcement.
  • Centaur has increased sales since launching Woxheal® in FY 2020/2021 by 210% in FY 2021/2022 and by 84% in the first 9 months of FY 2022/2023.
  • Centaur is behind Woxheal® with considerable advertising resources, so that the company expects a steady increase in sales in the medium term.
  • In the areas of medical development, marketing and production, the cooperation between Dermatools Biotech GmbH, bioXXmed and Centaur will be intensified.

Promontory Therapeutics Appoints Stan Musial as Chief Financial Officer

Retrieved on: 
Monday, November 28, 2022
NCI, CFO, Immunogenic cell death, History, Executive, Temple University, Darmstadt, Merck Group, Therapy, Biotechnology, MBA, Damage-associated molecular pattern, BS, Certified Public Accountant, IPO, Tumor microenvironment, Orphan drug, Trial of the century, Assertio Therapeutics, CPA, B cell, PD, KPMG, Research, State university system, Merck Serono, Promontory, Avelumab, Management, Pharmaceutical industry

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the appointment of Stanley J. Musial, CPA, MBA, as Chief Financial Officer. Musial brings over 25 years of financial, strategic and managerial experience with public and private biotechnology companies, with a demonstrated history in capital raising, IPO execution, mergers and acquisitions, corporate development and investor relations.

Key Points: 
  • NEW YORK, Nov. 28, 2022 /PRNewswire/ -- Promontory Therapeutics Inc. , a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, todayannounced the appointment ofStanley J. Musial, CPA, MBA, as Chief Financial Officer.
  • "We welcome Stan to the Promontory team at an exciting and pivotal time in our corporate development.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.
  • To learn more about Promontory Therapeutics, visit the company's website here .

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Retrieved on: 
Thursday, October 27, 2022
Science, Industry, ID, Travel, Industrial internet of things, Technology, Organization, Syringe, Trust, Digitalization, Industrial, Administration, Merck, Automation, Darmstadt, Online shopping

The proof of concept aims to transform the pharma supply chain by creating digital twins for primary packaging.

Key Points: 
  • The proof of concept aims to transform the pharma supply chain by creating digital twins for primary packaging.
  • "At Merck, we develop innovative digital solutions to help companies exploit the exciting advantages of the Industrial Internet of Things (IIoT) and create digital twins they can really trust.
  • We are proud to be a digital sparring partner to help Gerresheimer realize this by putting our patented digital technologies at their service," said Thomas Endress, Executive Director of EMD Digital at Merck.
  • With the jointly developed solution, Gerresheimer's physical primary packaging is provided with a trusted "key", enabling access to its digital twin.

Grid Connect, PEAK-System showcase diagnostics software, hardware for auto test

Retrieved on: 
Thursday, October 20, 2022
Grid-connected photovoltaic power system, Communication, NVH, Bus, Auto, ISO 9001:2015, PCAN, OEM, Grid, Program, Partnership, Software, Silver Peak Systems, Darmstadt, Industry, CEO, Vibration, Noise, Solution, Engineering, Medical device

NAPERVILLE, Ill., Oct. 20, 2022 /PRNewswire-PRWeb/ -- From October 25-27, 2022, Grid Connect, Inc. and Germany-based PEAK-System Technik GmbH will jointly showcase their latest CAN Bus hardware and software for vehicle telematics, diagnostics, and testing at the Automotive Testing Expo in Novi, Michigan's Suburban Collection Showcase (booth: 11046).

Key Points: 
  • "We've partnered with Grid Connect and are exhibiting together at the Auto Testing Expo, in part, because Grid supports test lab managers and engineers who buy our products like they would their own."
  • "In partnership with PEAK-System, we've brought a variety of hardware to this year's expo that test lab managers can use for diagnostics," added Adam Justice, CEO of Grid Connect.
  • "But we can also customize our products to the specs an engineer needs, which saves time and money for auto test pros."
  • Grid Connect's products range from custom OEM smart devices and security controllers to bridges, switches, and diagnostics tools.

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, August 11, 2022
TME, ESMO, Merck Group, Trillium, Survival, Oncolytics Biotech, ONC, Risk, CAR, Letrozole, AB, Breast, 2005 Tour de France, Stage 1 to Stage 11, Breast cancer, Mouse, Neoplasm, Industry, CFO, Cancer, Brain, TSX, Poster, European Society for Medical Oncology, Pfizer, Merck, PR, Patient, Pelareorep, Roche, Therapy, International, Company, Darmstadt, Prognosis, Acquisition, Pancreatic cancer, Data, Paclitaxel, NASDAQ, LINK, Skin cancer, Science Translational Medicine, Oncology, Progression-free survival, Immune system, Investor relations, Medical imaging, Pharmaceutical industry, Video game

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.
  • Operating expense for the second quarter of 2022 was $2.8 million, compared to $3.5 million for the second quarter of 2021.
  • R&D expense for the second quarter of 2022 was $3.2 million, compared to $3.2 million for the second quarter of 2021.
  • Net cash used in operating activities for the second quarter of 2022 was $6.9 million, compared to $6.8 million in the second quarter of 2021.

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, August 11, 2022
TME, ESMO, Merck Group, Trillium, Survival, Oncolytics Biotech, ONC, Risk, CAR, Letrozole, AB, Breast, 2005 Tour de France, Stage 1 to Stage 11, Breast cancer, Mouse, Neoplasm, Industry, CFO, Cancer, Brain, TSX, Poster, European Society for Medical Oncology, Pfizer, Merck, PR, Patient, Pelareorep, Roche, Therapy, International, Company, Darmstadt, Prognosis, Acquisition, Pancreatic cancer, Data, Paclitaxel, NASDAQ, LINK, Skin cancer, Science Translational Medicine, Oncology, Progression-free survival, Immune system, Investor relations, Medical imaging, Pharmaceutical industry, Video game

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.
  • Operating expense for the second quarter of 2022 was $2.8 million, compared to $3.5 million for the second quarter of 2021.
  • R&D expense for the second quarter of 2022 was $3.2 million, compared to $3.2 million for the second quarter of 2021.
  • Net cash used in operating activities for the second quarter of 2022 was $6.9 million, compared to $6.8 million in the second quarter of 2021.

DGAP-News: Temedica wins further renowned industry representatives for expert advisory board

Retrieved on: 
Tuesday, April 26, 2022
MSD, Sentinel, Drug development, CEO, NIH, Board of directors, World government, US Foods, Industry, Principal investigator, Research, Federalisation of the European Union, Food, Merck Group, European Federation of Pharmaceutical Industries and Associations, Federal Joint Committee (Germany), Patient, Merck, Hospital, Electronics, EFPIA, Health, BioNTech, Method, Hewlett-Packard, Epidemiology, International Society for Pharmacoepidemiology, Division, Pharmaceutical Association of Mauritius, Advisory board, International Society, Veterinary medicine, Cone Health Women's Hospital, Plasma protein binding, National Executive Board of the Boy Scouts of America, HIV disease progression rates, FDA, Harvard Medical School, Merck & Co., Darmstadt, University of Hanover, Association, Medical device, Pharmaceutical industry, Medicine, Aetion, Pharmacoepidemiology

Dr. Rainer Hess, Prof. Dr. Norbert Klusen and Rudi Lamprecht will continue to serve on the expert advisory board ( https://temedica.com/en/about-us/#experts ).

Key Points: 
  • Dr. Rainer Hess, Prof. Dr. Norbert Klusen and Rudi Lamprecht will continue to serve on the expert advisory board ( https://temedica.com/en/about-us/#experts ).
  • Gloria Seibert, Founder & Chief Executive Officer at Temedica, said:
    "We are proud to win further internationally renowned personalities for our expert advisory board.
  • With Dr. Seimetz, Dr. Oschmann, and Prof. Dr. Dr. Schneeweiss, we expand our advisory board with high-caliber and broad expertise.
  • I am delighted to join Temedica as part of their expert advisory board and to help harness the enormous potential of real-world evidence for the entire industry."

Vertical Flight Society Announces 2022 Individual Recipients of Its Prestigious Awards

Retrieved on: 
Wednesday, March 16, 2022
Pennsylvania State University, Technology, Forum, Darmstadt, Noise, Sikorsky, Goal, Communication, VTOL, Vertical Flight Society, Acoustics, Policy, History, LinkedIn, Twitter, Bagai, FVL, LLC, Government, Aerospace engineering, Leadership, EVTOL, Instagram, Alldridge, Mechanic, VFS, Bell, Vimeo, Niagara Aerospace Museum, Principal, Boeing, Social media, Henry Ford Technical Fellow, Achievement, YouTube, Niagara Falls, Facebook, Future Vertical Lift, Safety, Medicine, Certification, NASA, Industry, Airline, Management, Surveying, Society, United Therapeutics, Buffalo

FAIRFAX, Va., March 16, 2022 /PRNewswire-PRWeb/ --The Vertical Flight Society (VFS) today announced the 2022 individual recipients of its prestigious awards program.

Key Points: 
  • FAIRFAX, Va., March 16, 2022 /PRNewswire-PRWeb/ --The Vertical Flight Society (VFS) today announced the 2022 individual recipients of its prestigious awards program.
  • Since its establishment in 1944, VFS Awards have paid tribute to the outstanding leaders of vertical flight and served as a catalyst for stimulating technological advances.
  • The annual Franois-Xavier Bagnoud Award is given to an individual Society member under the age of 35 for career-to-date outstanding contributions to vertical flight technology.
  • The Vertical Flight Society was founded as the American Helicopter Society in 1943 by the pioneers of the helicopter industry, who believed that technological cooperation and collaboration was essential to advance vertical flight.